Peptide receptor radionuclide therapy (PRRT)

RADIATION3 trials

Sponsors

University of Chicago, University Health Network, Toronto, Azienda USL Reggio Emilia - IRCCS

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromePancreas CancerPancreatic Neuroendocrine TumorParagangliomasPheochromocytomas

Phase 1

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

WithdrawnNCT05610826

University of ChicagoPancreas Cancer, Pancreatic Neuroendocrine Tumor

Start: 2023-03-07End: 2024-09-11Updated: 2024-10-26

Unknown Phase

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

RecruitingNCT06510868

University Health Network, TorontoAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2024-08-01End: 2029-06-30Target: 45Updated: 2026-03-05

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)

Not yet recruitingNCT07538791

Azienda USL Reggio Emilia - IRCCSParagangliomas, Pheochromocytomas

Start: 2026-08-30End: 2028-04-30Target: 210Updated: 2026-07-17